We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




High Dose Radiation Improves Lung Cancer Survival

By MedImaging International staff writers
Posted on 28 Apr 2009
Print article
Higher doses of radiation combined with chemotherapy improve survival in patients with stage III lung cancer, according to a new study's findings.

Standard treatment for this stage of lung cancer--when the tumor is typically too large to be removed through surgery--involves a combination of radiation therapy with chemotherapy. But, this new study finds, giving chemotherapy at the same time as the radiation enhances the effect of both. Furthermore, increasing the dose of radiation over the course of treatment also increased survival.

"When patients are diagnosed with stage III lung cancer, surgery is often not an option, and survival rates are typically quite low. Finding new ways to improve survival, even in small increments, is crucial," noted senior study author Feng-Ming Kong, M.D., Ph.D., associate professor of radiation oncology at the University of Michigan (U-M) Comprehensive Cancer Center (Ann Arbor, MI, USA) and chief of radiation oncology at the Ann Arbor Veterans Administration (VA) Healthcare System.

The study, published in the April 1, 2009, issue of the International Journal of Radiation Oncology Biology Physics, evaluated 237 patients who had been treated for stage III non-small cell lung cancer at U-M and the VA Ann Arbor. The researchers compared survival among patients treated with radiation alone, with radiation followed by chemotherapy, and with radiation and chemotherapy administered at the same time. Thirty-one of the patients were also enrolled in a study in which the radiation dose was increased throughout the course of the treatment.

Patients treated with radiation alone had the worst overall survival rates, living only an average 7.4 months after diagnosis. Adding chemotherapy increased survival to 14.9 months when it was administered after completing radiation and 15.8 months when administered at the same time as radiation. After five years, 19.4% of the patients receiving concurrent chemotherapy were still alive, compared to only 7.5% of patients receiving sequential chemotherapy. "Our study shows chemotherapy helps, and high dose radiation helps. But it's challenging to administer these treatments at the same time because of the potential toxicity associated with the high dose radiation," Dr. Kong said.

U-M researchers are currently looking at utilizing positron emission tomography (PET) imaging during the course of lung cancer treatment to customize high dose radiation therapy in many individual patients. As the tumor becomes smaller during treatment, increasing the radiation dose will become more tolerable because it is targeting a smaller area. The U-M researchers believe this strategy could lead to improved treatment outcomes in many patients. Dr. Kong currently leads a clinical trial that is following patients through their treatment to look at the impact on survival of increasing radiation dose.

Related Links:
University of Michigan Comprehensive Cancer Center



Ultrasound Table
Women’s Ultrasound EA Table
Portable Color Doppler Ultrasound System
S5000
40/80-Slice CT System
uCT 528
Radiology Software
DxWorks

Print article

Channels

Radiography

view channel
Image: AI can identify “mammographically-visible” types of interval cancers earlier by flagging them at the time of screening (Photo courtesy of ScreenPoint Medical)

AI Improves Early Detection of Interval Breast Cancers

Interval breast cancers, which occur between routine screenings, are easier to treat when detected earlier. Early detection can reduce the need for aggressive treatments and improve the chances of better outcomes.... Read more

Nuclear Medicine

view channel
Image: In vivo imaging of U-87 MG xenograft model with varying mass doses of 89Zr-labeled KLG-3 or isotype control (Photo courtesy of L Gajecki et al.; doi.org/10.2967/jnumed.124.268762)

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.